Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis

Molecular Pharmacology

Volumn 59, Issue 4, 2001, Pages 909-919

  Afzelius, Lovisa ^a,b   Zamora, Ismael ^a   Ridderström, Marianne ^a   Andersson, Tommy B ^a   Karlén, Anders ^b   Masimirembwa, Collen M ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DICOUMAROL; FLUVOXAMINE; KAEMPFEROL; MICONAZOLE; OMEPRAZOLE SULFONE; PANTOPRAZOLE; PHENYLBUTAZONE; PHENYTOIN; PROGESTERONE; PYRANOCOUMARIN DERIVATIVE; PYRIMETHAMINE; QUERCETIN; QUININE; RABEPRAZOLE; SULFAPHENAZOLE; TIABENDAZOLE; WARFARIN; ZAFIRLUKAST;

ARTICLE; CALCULATION; DRUG COMPETITION; DRUG STRUCTURE; ENERGY; ENZYME ACTIVE SITE; ENZYME INHIBITION; MATHEMATICAL MODEL; MOLECULAR INTERACTION; MUTAGENESIS; PRIORITY JOURNAL; RABBIT; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

EID: 0035065393     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.4.909     Document Type: Article

References (45)

1. Evaluation of model discrimination, parameter estimation and goodness of fit in nonlinear regression problems by test statistics distributions
2. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s
3. D-optimal designs in QSAR
4. Interlaboratory comparision of the assessment of P450 activities in human hepatic microsomal samples
5. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6
6. Novel approach to predicting P450 mediated drug metabolism: Development of combined protein and pharmacophore model for CYP2D6
7. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity
8. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
9. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors
10. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
11. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6
12. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates
13. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
14. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences
15. Enzymatic determinants of the substrate specificity of CYP2C9: Role of B'-C loop residues in providing the π-π stacking anchor site for warfarin binding
16. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9
17. Activation of CYP2C9 by dapsone and analogs
18. High catalytic activity of human cytochrome P450 co-expressed with human NADPH- cytochrome P450 reductase in Escherichia coli
19. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase)
20. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9
21. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19
22. Electronic models for cytochrome P450 oxidations
23. QSAR and 3D QSAR in drug design. Part 1: Methodology
24. QSAR and 3D QSAR in drug design Part 2: Applications and problems
25. Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries
26. The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling
27. Heterologous expression and kinetic characterization of human cytochromes P-450: Validation of a pharmaceutical tool for drug metabolism research
28. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems
29. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
30. Quantitative structure-activity relationships (QSAR) study of flavonoid derivatives for inhibition of cytochrome P450 1A2
31. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents
32. GRid-INdependent Descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors
33. Homology modeling and substrate binding study of human CYP2C9 enzyme
34. A close family resemblance: The importance of structure in understanding cytochromes P450
35. The substrate binding site of human liver cytochrome P450 2C9: An NMR study
36. A refined 3-dimensional QSAR of cytochrome P450 2C9: Computational predictions of drug interactions
37. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function
38. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: Active site characteristics
39. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates
40. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies
41. In vitro and in vivo drug interactions involving human CYP3A
42. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity
43. Multivariate data analysis in chemistry
44. Principal component analysis